Acamprosate in alcohol dependence: Implications of a unique mechanism of action

Journal of Addiction Medicine

Volumn 1, Issue 3, 2007, Pages 115-125

  Littleton, John M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Acamprosate; Alcohol dependence; GABA; Glutamate; NMDA

Indexed keywords

EID: 38849099417     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318156c26f     Document Type: Review

References (81)

1. Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991- 1992 and 2001-2002. Drug Alcohol Depend. 2004;74:223-234. (Pubitemid 38759777)
2. Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs. 2004;18:485-504. (Pubitemid 38829945)
3. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546-1552. (Pubitemid 41070891)
4. Modesto-Lowe V, Fritz EM. The opioidergic-alcohol link: implications for treatment. CNS Drugs. 2005;19:693-707. (Pubitemid 41305986)
5. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
6. De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav. 2004;29:1325-1339. (Pubitemid 39165992)
7. Tambour S, Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol. 2007;21:9-28. (Pubitemid 46096179)
8. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World. 1998;22:13-24.
9. Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict. 2003;12 (Suppl 1):S3-11.
10. Roberto M, Madamba SG, Moore SD, et al. Ethanol increases GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons. Proc Natl Acad Sci USA. 2003;100:2053-2058. (Pubitemid 36254572)
11. Roberto M, Treistman SN, Pietrzykowski AZ, et al. Actions of acute and chronic ethanol on presynaptic terminals. Alcohol Clin Exp Res. 2006; 30:222-232. (Pubitemid 43341372)
12. Mihic SJ, Harris RA. Alcohol actions at the GABAA receptor/chloride channel complex. In: Deitrich RA, Erwin VG, eds. Pharmacological Effects of Ethanol on the Nervous System. Boca Raton, FL: CRC Press; 1996:51-72.
13. Kuriyama K, Mizutani H, Hirouchi M, et al. Alteration in cerebralGABAB receptor functions during formation of alcohol dependence. Alcohol Alcohol. 1994;2(Suppl):193-197.
14. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995;152:332-340.
15. Nevo I, Hamon M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int. 1995;26:305-336.
16. Harris BR, Prendergast MA, Gibson DA, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res. 2002;26:1779-1793. (Pubitemid 36008614)
17. Awad H, Hubert GW, Smith Y, et al. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neuroscience. 2000;20:7871-7879.
18. Krystal JH, Petrakis IL, Mason G, et al. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther. 2003;99:79-94. (Pubitemid 36694751)
19. Franken IH, Booij J, van den Brink W. The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol. 2005; 526:199-206. (Pubitemid 41744117)
20. Rassnick S, Stinus L, Koob GF. The effects of 6-hydroxydopamine lesions of the nucleus accumbens and the mesolimbic dopamine system on oral self-administration of ethanol in the rat. Brain Res. 1993;623: 16-24. (Pubitemid 23267384)
21. Ikemoto S, McBride WJ, Murphy JM, et al. 6-OHDA-lesions of the nucleus accumbens disrupt the acquisition but not the maintenance of ethanol consumption in the alcohol-preferring P line of rats. Alcohol Clin Exp Res. 1997;21:1042-1046. (Pubitemid 27407168)
22. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem. 2004;4:39-50. (Pubitemid 38849357)
23. Barr CS, Schwandt M, Lindell SG, et al. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry. 2007;64: 369-376. (Pubitemid 46376788)
24. Xiao C, Zhang J, Krnjevic K, et al. Effects of ethanol on midbrain neurons: role of opioid receptors. Alcohol Clin Exp Res. 2007;31:1106-1113. (Pubitemid 46934389)
25. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanolinduced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993;621:137-140. (Pubitemid 23242172)
26. Lee YK, Park SW, Kim YK, et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol. 2005;40:297-301.
27. Zalewska-Kaszubska J, Gorska D, Dyr W, et al. Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone. Pharmacol Biochem Behav. 2006;85:155-159. (Pubitemid 44772917)
28. Mitchell JM, Tavares VC, Fields HL, et al. Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls. Neuropsychopharmacology.2007;32:439-449. (Pubitemid 46106950)
29. Maren S. Synaptic mechanisms of associative memory in the amygdala. Neuron. 2005;47:783-786. (Pubitemid 41266945)
30. Herman BH, Vocci F, Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology. 1995;13:269-293. (Pubitemid 26008848)
31. Siggins GR, Martin G, Roberto M, et al. Glutamatergic transmission in opiate and alcohol dependence. Ann NY Acad Sci. 2003;1003:196-211. (Pubitemid 38083057)
32. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997;129:99-111. (Pubitemid 27033665)
33. De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinencepromoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19:517-537. (Pubitemid 41058377)
34. Melchior CL, Tabakoff B. Features of environment-dependent tolerance to ethanol. Psychopharmacology (Berl). 1985;87:94-100. (Pubitemid 15242020)
35. Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res. 1998;22:3-9. (Pubitemid 28139190)
36. Koob GF. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction. 2006;101 (Suppl 1):23-30. (Pubitemid 44199493)
37. Johnson BA, Koob GF, Schuckit MA, et al. Understanding and treating alcohol dependence. Alcohol Clin Exp Res. 2006;30:567-584. (Pubitemid 43341363)
38. Drummond DC. What does cue-reactivity have to offer clinical research? Addiction. 2000;95 (Suppl 2):S129-144.
39. Blair HT, Schafe GE, Bauer EP, et al. Synaptic plasticity in the lateral amygdala: a cellular hypothesis of fear conditioning. Learn Mem. 2001;8:229-242. (Pubitemid 32959636)
40. Le AD, Harding S, Juzytsch W, et al. The role of corticotrophinreleasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl). 2000;150:317-324. (Pubitemid 30447852)
41. Zhao Y, Dayas CV, Aujla H, et al. Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanolseeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci. 2006;26:9967-9974. (Pubitemid 44477158)
42. Naassila M, Hammoumi S, Legrand E, et al. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res. 1998;22:802-809. (Pubitemid 28292462)
43. al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 1998;22:810-814. (Pubitemid 28292463)
44. Popp RL, Lovinger DM. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol. 2000;394:221-231. (Pubitemid 30195705)
45. Harris BR, Gibson DA, Prendergast MA, et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res. 2003;27:1724-1735. (Pubitemid 37444358)
46. Heidinger V, Manzerra P, Wang XQ, et al. Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J Neurosci. 2002;22:5452-5461. (Pubitemid 35386467)
47. Mayer S, Harris BR, Gibson DA, et al. Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol Clin Exp Res. 2002;26:1468-1478. (Pubitemid 35192307)
48. Mayer S, Harris B, Gibson DA, et al. Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcohol Clin Exp Res. 2002;26:655-662. (Pubitemid 34522672)
49. Hu XJ, Ticku MK. Chronic ethanol treatment upregulates the NMDA receptor function and binding in mammalian cortical neurons. Brain Res Mol Brain Res. 1995;30:347-356.
50. Hu XJ, Follesa P, Ticku MK. Chronic ethanol treatment produces a selective upregulation of the NMDA receptor subunit gene expression in mammalian cultured cortical neurons. Brain Res Mol Brain Res. 1996; 36:211-218. (Pubitemid 26095580)
51. Harris BR, Ferchmin PA, Blanchard JA, et al. The sodium salt of acamprosate inhibits the potentiation of NMDA responses by a selective mGluR5 agonist. Poster presented at: Research Society on Alcoholism, Vancouver, Canada; 2004.
52. Cunningham CL, Fidler TL, Hill KG. Animal models of alcohol's motivational effects. Alcohol Res Health. 2000;24:85-92.
53. Le Magnen J, Tran G, Durlach J, et al. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol. 1987;4:97-102. (Pubitemid 17073486)
54. Spanagel R, Holter SM, Allingham K, et al. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol. 1996;305:39-44. (Pubitemid 26195983)
55. Heyser CJ, Schulteis G, Durbin P, et al. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology. 1998;18: 125-133. (Pubitemid 28026682)
56. Holter SM, Landgraf R, Zieglgansberger W, et al. Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation. Alcohol Clin Exp Res. 1997;21:862-868. (Pubitemid 27355684)
57. Morse AC, Koob GF. Intra-BNST acamprosate attenuates withdrawalinduced increases in ethanol consumption in dependent rats. Poster presented at: Society for Neuroscience, Orlando, FL; 2002.
58. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci. 1992;654:171-191.
59. Olive MF, Nannini MA, Ou CJ, et al. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol. 2002;437:55-61. (Pubitemid 34178386)
60. Cano-Cebrian MJ, Zornoza-Sabina T, Guerri C, et al. Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:119-125. (Pubitemid 36286870)
61. Cano-Cebrian MJ, Zornoza-Sabina T, Guerri C, et al. Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus. Naunyn Schmiedebergs Arch Pharmacol. 2003;368:324-327. (Pubitemid 37372557)
62. Spanagel R, Zieglgansberger W, Hundt W. Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat. Eur J Pharmacol. 1996;305:51-56. (Pubitemid 26195985)
63. Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav. 1989;32:607-611. (Pubitemid 19162376)
64. Dahchour A, De Witte P. Acamprosate decreases the hypermotility during repeated ethanol withdrawal. Alcohol. 1999;18:77-81. (Pubitemid 29269903)
65. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res. 1998;82:107-114. (Pubitemid 28341671)
66. Dahchour A, De Witte P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. Alcohol Clin Exp Res. 2003;27:465-470. (Pubitemid 36343291)
67. Quertemont E, Brabant C, De Witte P. Acamprosate reduces contextdependent ethanol effects. Psychopharmacology (Berl). 2002;164:10-18. (Pubitemid 35203837)
68. Bachteler D, Economidou D, Danysz W, et al. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology. 2005;30:1104-1110. (Pubitemid 40720968)
69. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680. (Pubitemid 26269327)
70. Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
71. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
72. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51-63. (Pubitemid 38114023)
73. Bouza C, Angeles M, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99:811-828. (Pubitemid 38869838)
74. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295: 2003-2017. (Pubitemid 44794003)
75. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo- controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40:383-393. (Pubitemid 43816589)
76. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003; 60:92-99. (Pubitemid 36070869)
77. Feeney GF, Connor JP, Young RM, et al. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006;41:321-327.
78. Crabbe JC. Alcohol and genetics: new models. Am J Med Genet. 2002;114:969-974. (Pubitemid 35379242)
79. Samson HH. The microstructure of ethanol drinking: genetic and behavioral factors in the control of drinking patterns. Addiction. 2000;95 (Suppl) 2:S61-72. (Pubitemid 30650372)
80. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25: 1335-1341. (Pubitemid 32868343)
81. Berglund M, Thelander S, Salaspuro M, et al. Treatment of alcohol abuse: an evidence-based review. Alcohol Clin Exp Res. 2003;27: 1645-1656. (Pubitemid 37287595)